메뉴 건너뛰기




Volumn 65, Issue 1, 2014, Pages 132-138

Uroplakin II outperforms uroplakin III in diagnostically challenging settings

Author keywords

Biomarkers; Immunohistochemistry; Uroplakin; Urothelial carcinoma

Indexed keywords

ANTIBODY; UNCLASSIFIED DRUG; UROPLAKIN 2; UROPLAKIN 2 ANTIBODY; UROPLAKIN 3; UROPLAKIN 3 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER; UPK2 PROTEIN, HUMAN; UPK3A PROTEIN, HUMAN;

EID: 84902110632     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12360     Document Type: Article
Times cited : (48)

References (18)
  • 2
    • 34247630071 scopus 로고    scopus 로고
    • Placental s100 (s100p) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray
    • Higgins JP, Kaygusuz G, Wang L et al. Placental s100 (s100p) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am. J. Surg. Pathol. 2007; 31; 673-680.
    • (2007) Am. J. Surg. Pathol. , vol.31 , pp. 673-680
    • Higgins, J.P.1    Kaygusuz, G.2    Wang, L.3
  • 3
    • 84891623727 scopus 로고    scopus 로고
    • GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors
    • Miettinen M, McCue PA, Sarlomo-Rikala M et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2013; 38; 13-22.
    • (2013) Am. J. Surg. Pathol. , vol.38 , pp. 13-22
    • Miettinen, M.1    McCue, P.A.2    Sarlomo-Rikala, M.3
  • 4
    • 84876487361 scopus 로고    scopus 로고
    • Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules
    • Gandou C, Harada K, Sato Y et al. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum. Pathol. 2013; 44; 811-821.
    • (2013) Hum. Pathol. , vol.44 , pp. 811-821
    • Gandou, C.1    Harada, K.2    Sato, Y.3
  • 5
    • 0034424842 scopus 로고    scopus 로고
    • Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas
    • Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol. 2000; 113; 683-687.
    • (2000) Am. J. Clin. Pathol. , vol.113 , pp. 683-687
    • Kaufmann, O.1    Volmerig, J.2    Dietel, M.3
  • 6
    • 0036305276 scopus 로고    scopus 로고
    • Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma
    • Brown HM, Wilkinson EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum. Pathol. 2002; 33; 545-548.
    • (2002) Hum. Pathol. , vol.33 , pp. 545-548
    • Brown, H.M.1    Wilkinson, E.J.2
  • 7
    • 0036859760 scopus 로고    scopus 로고
    • Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma
    • Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum. Pathol. 2002; 33; 1136-1140.
    • (2002) Hum. Pathol. , vol.33 , pp. 1136-1140
    • Mhawech, P.1    Uchida, T.2    Pelte, M.F.3
  • 8
    • 0037215340 scopus 로고    scopus 로고
    • Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas
    • Parker DC, Folpe AL, Bell J et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am. J. Surg. Pathol. 2003; 27; 1-10.
    • (2003) Am. J. Surg. Pathol. , vol.27 , pp. 1-10
    • Parker, D.C.1    Folpe, A.L.2    Bell, J.3
  • 9
    • 84870860776 scopus 로고    scopus 로고
    • Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung
    • Gruver AM, Amin MB, Luthringer DJ et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch. Pathol. Lab. Med. 2012; 136; 1339-1346.
    • (2012) Arch. Pathol. Lab. Med. , vol.136 , pp. 1339-1346
    • Gruver, A.M.1    Amin, M.B.2    Luthringer, D.J.3
  • 10
    • 84904465568 scopus 로고    scopus 로고
    • A newly developed anti-uroplakin II monoclonal antibody with increased sensitivity in urothelial carcinoma of the bladder
    • Hoang L, Qi W, Bremer R et al. A newly developed anti-uroplakin II monoclonal antibody with increased sensitivity in urothelial carcinoma of the bladder. Mod. Pathol. 2013; 26(Suppl 2); 1A-534A.
    • (2013) Mod. Pathol. , vol.26 , Issue.2 SUPPL
    • Hoang, L.1    Qi, W.2    Bremer, R.3
  • 11
    • 84863409904 scopus 로고    scopus 로고
    • P63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system
    • Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP. P63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. Histopathology 2012; 60; 597-608.
    • (2012) Histopathology , vol.60 , pp. 597-608
    • Carvalho, J.C.1    Thomas, D.G.2    McHugh, J.B.3    Shah, R.B.4    Kunju, L.P.5
  • 12
    • 84865485319 scopus 로고    scopus 로고
    • Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship
    • Gupta R, Billis A, Shah RB et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am. J. Surg. Pathol. 2012; 36; 1265-1278.
    • (2012) Am. J. Surg. Pathol. , vol.36 , pp. 1265-1278
    • Gupta, R.1    Billis, A.2    Shah, R.B.3
  • 13
    • 84888068230 scopus 로고    scopus 로고
    • The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas
    • Gonzalez-Roibon N, Albadine R, Sharma R et al. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas. Hum. Pathol. 2013; 44; 2651-2657.
    • (2013) Hum. Pathol. , vol.44 , pp. 2651-2657
    • Gonzalez-Roibon, N.1    Albadine, R.2    Sharma, R.3
  • 14
    • 84885022366 scopus 로고    scopus 로고
    • GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma
    • So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod. Pathol. 2013; 26; 1365-1370.
    • (2013) Mod. Pathol. , vol.26 , pp. 1365-1370
    • So, J.S.1    Epstein, J.I.2
  • 15
    • 84888129675 scopus 로고    scopus 로고
    • Is GATA3 expression maintained in regional metastases? A study of paired primary and metastatic urothelial carcinomas
    • Zhao L, Antic T, Witten D et al. Is GATA3 expression maintained in regional metastases? A study of paired primary and metastatic urothelial carcinomas. Am. J. Surg. Pathol. 2013; 37; 1876-1881.
    • (2013) Am. J. Surg. Pathol. , vol.37 , pp. 1876-1881
    • Zhao, L.1    Antic, T.2    Witten, D.3
  • 16
    • 84866607353 scopus 로고    scopus 로고
    • Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung
    • Chang A, Amin A, Gabrielson E et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am. J. Surg. Pathol. 2012; 36; 1472-1476.
    • (2012) Am. J. Surg. Pathol. , vol.36 , pp. 1472-1476
    • Chang, A.1    Amin, A.2    Gabrielson, E.3
  • 17
    • 84872683637 scopus 로고    scopus 로고
    • Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract
    • Gulmann C, Paner GP, Parakh RS et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum. Pathol. 2013; 44; 164-172.
    • (2013) Hum. Pathol. , vol.44 , pp. 164-172
    • Gulmann, C.1    Paner, G.P.2    Parakh, R.S.3
  • 18
    • 33646250894 scopus 로고    scopus 로고
    • Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betae12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma
    • Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betae12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am. J. Clin. Pathol. 2006; 125; 675-681.
    • (2006) Am. J. Clin. Pathol. , vol.125 , pp. 675-681
    • Kunju, L.P.1    Mehra, R.2    Snyder, M.3    Shah, R.B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.